Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday October 19, 2009

DrStockPick.com Stock Report!

AMLN, PWRM, MMM, CSRH, MYL, CVAT, STEM, AQNM

**************************************************************

AMLN, Amylin Pharmaceuticals, Inc.

AMLN is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines.

AMLN will webcast its Quarterly Update Conference Call for the third quarter of 2009 on Tuesday, October 20, 2009 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin’s president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the third quarter of 2009.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday September 28, 2009

DrStockPick.com Stock Report!

PWRM, SHMN, MRK, TSPG, AQNM

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete

...

Mylan Inc. (MYL) entered into a strategic partnership with Biocon Ltd to expand into the area of biotechnology. Biocon has a strong portfolio of biopharmaceutical drugs that include insulin, erythropoietin and monoclonal antibodies. The collaboration will help both companies to develop, manufacture and commercialize generic biotech medicines without duplicating associated costs. The deal mainly focuses on monoclonal antibodies used to treat diseases such as cancer and rheumatoid arthritis.

Mylan develops, manufactures, markets, licenses, and distributes generic, branded, and branded generic pharmaceutical products, as well as active pharmaceutical ingredients (APIs). In order to expand its product line, Mylan has been pretty active in forming strategic alliances with pharmaceutical companies to develop products or to launch distribution and licensing arrangements. After the acquisition of Merck Generics and Matrix Labs, Mylan is now the third-largest generic company in the world.

Mylan has a robust generic product pipeline and the total

...

Initiating Teva Pharmaceuticals with a BuyWe are initiating coverage on Teva Pharmaceutical Industries (TEVA) with a Buy recommendation and a price target of $52.Teva posted strong financial results in 2008 despite the global recession. The company witnessed robust top- and bottom-line growth during the year. We expect the strong performance to continue, and believe the current share represents an attractive entry point.We believe Teva has significant growth opportunity thanks to many products going off-patent in the next few years, several for which the company has filed ANDAs (abbreviated new drug applications). The number of ANDAs filed by the company with the U.S. Food and Drug Administration (FDA) now stands at 201, representing more than $110 billion in branded sales. New generic product launches over the next few years should help drive sales.The acquisition of Barr Pharma in December 2008 should ...

Dr. Reddy's Laboratories, Ltd. (RDY) is a global pharmaceutical company located in Hyderabad, India. RDY produces active pharmaceutical ingredients (API), finished dosage forms and branded and generic pharmaceutical products for the global market.While fiscal 2007 was a very strong year for the company, the lack of significant generic product launches, intense pricing pressure in the generics market, and declining revenues from the Mexico CPS and betapharm businesses took a toll on the company's performance in fiscal 2008. Though we expect RDY to swing back to growth in fiscal 2009, we believe it will take some time for the company to resolve the situation in Germany and Mexico.This, along with the lack of any significant near-term catalysts, is likely to keep the shares trading in a tight range over the next few months. We maintain our Hold rating with a price target of $10 (INR ...

Mylan, Inc. (MYL) is engaged in the development, manufacture, marketing, licensing, and distribution of generic, branded, and branded generic pharmaceutical products, as well as active pharmaceutical ingredients (APIs). With the acquisition of Merck Generics and Matrix Labs, Mylan is now the third largest generic company in the world.We expect the Merck Generics acquisition to allow Mylan to expand its footprints in non-U.S. markets and to contribute significantly to long-term growth. Mylan also announced certain strategic initiatives which should help drive long-term growth. Besides this, Mylan has been working on improving its capital structure, which should help ease concerns regarding its liquidity position.The company's results over the past two quarters exceeded both ours and the Street's expectations. The strong performance should continue going into 2009. We maintain our Hold rating with a target price of $10.Arpita Dutt contributed to this report....

Barr Pharmaceuticals, Inc. (BRL) is a global specialty pharmaceutical company engaged in the development, manufacture and marketing of branded and generic drugs. On July 18, 2008, Barr announced that it has entered into an agreement with Teva Pharmaceuticals (TEVA) whereby the latter will acquire Barr for $7.46 billion plus the assumption of net debt of approximately $1.5 billion. We had issued a Sell rating on Barr after the company posted disappointing first-quarter results and slashed its full-year outlook. However, we moved back to a Hold rating following the Teva takeover announcement. This offer has come at the right time for Barr -- the deal should close later this year. We maintain a Hold rating with a $65 price target.Barr markets and sells generic pharmaceutical products in the U.S., Europe and certain other countries in the rest of the world. Its generic product portfolio ...